# PYRIDOSTIGMINE BROMIDE- pyridostigmine bromide tablet, extended release

NuCare Pharmaceuticals, Inc.

-----


Pyridostigmine Bromide Extended-Release Tablets

(180 mg)

**Rx only** 

#### DESCRIPTION

Pyridostigmine bromide is an orally active cholinesterase inhibitor. Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide dimethylcarbamate. Its structural formula is:



Pyridostigmine bromide extended-release tablets are available as extended-release tablets containing 180 mg pyridostigmine bromide; each tablet also contains carnauba wax, copovidone, lactose, magnesium stearate, and silicon dioxide.

#### **CLINICAL PHARMACOLOGY**

Pyridostigmine bromide inhibits the destruction of acetylcholine by cholinesterase and thereby permits freer transmission of nerve impulses across the neuromuscular junction. Pyridostigmine is an analog of neostigmine, but differs from it in certain clinically significant respects; for example, pyridostigmine is characterized by a longer duration of action and fewer gastrointestinal side effects.

#### INDICATIONS AND USAGE

Pyridostigmine bromide is useful in the treatment of myasthenia gravis.

#### CONTRAINDICATIONS

Pyridostigmine bromide is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

## WARNINGS

Although failure of patients to show clinical improvement may reflect underdosage, it can also be indicative of overdosage. As is true of all cholinergic drugs, overdosage of pyridostigmine bromide may result in cholinergic crisis, a state characterized by increasing muscle weakness which, through involvement of the muscles of respiration, may lead to death. Myasthenic crisis due to an increase in the severity of the disease is also accompanied by extreme muscle weakness, and thus may be difficult to distinguish from cholinergic crisis on a symptomatic basis. Such differentiation is extremely important, since increases in doses of pyridostigmine bromide or other drugs of this class in the presence of cholinergic crisis or of a refractory or "insensitive" state could have grave consequences. Osserman and Genkins <sup>1</sup> indicate that the differential diagnosis of the two types of crisis may require the use of edrophonium chloride as well as clinical judgment. The treatment of the two conditions obviously differs radically. Whereas the presence of myasthenic crisis suggests the need for more intensive anticholinesterase therapy, the diagnosis of cholinergic crisis, according to Osserman and Genkins <sup>1</sup>, calls for the prompt *withdrawal* of all drugs of this type. The immediate use of atropine in cholinergic crisis is also recommended.

Atropine may also be used to abolish or obtund gastrointestinal side effects or other muscarinic reactions; but such use, by masking signs of overdosage, can lead to inadvertent induction of cholinergic crisis.

For detailed information on the management of patients with myasthenia gravis, the physician is referred to one of the excellent reviews such as those by Osserman and Genkins <sup>2</sup>, Grob <sup>3</sup> or Schwab <sup>4,5</sup>.

*Usage in Pregnancy:* The safety of pyridostigmine bromide during pregnancy or lactation in humans has not been established. Therefore, use of pyridostigmine bromide in women who may become pregnant requires weighing the drug's potential benefits against its possible hazards to mother and child.

## PRECAUTIONS

Pyridostigmine is mainly excreted unchanged by the kidney <sup>6,7,8</sup>. Therefore, lower doses may be required in patients with renal disease, and treatment should be based on titration of drug dosage to effect <sup>6,7</sup>.

#### **Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

## **ADVERSE REACTIONS**

The side effects of pyridostigmine bromide are most commonly related to overdosage and generally are of two varieties, muscarinic and nicotinic. Among those in the former group are nausea, vomiting, diarrhea, abdominal cramps, increased peristalsis, increased salivation, increased bronchial secretions, miosis and diaphoresis. Nicotinic side effects are comprised chiefly of muscle cramps, fasciculation and weakness. Muscarinic side effects can usually be counteracted by atropine, but for reasons shown in the preceding section the expedient is not without danger. As with any compound containing the bromide radical, a skin rash may be seen in an occasional patient. Such reactions usually subside promptly upon discontinuance of the medication.

## To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

## DOSAGE AND ADMINISTRATION

Pyridostigmine bromide is available in extended-release dosage form:

*Extended-Release Tablets* — each containing 180 mg pyridostigmine bromide. This form provides uniformly slow release, hence prolonged duration of drug action; it facilitates control of myasthenic symptoms with fewer individual doses daily. The immediate effect of a 180 mg extended-release tablet is about equal to that of a 60 mg immediate-release tablet; however, its duration of effectiveness, although varying in individual patients, averages 2  $_{1/2}$  times that of a 60 mg dose.

*Dosage:* The size and frequency of the dosage must be adjusted to the needs of the individual patient.

*Extended-Release Tablets* — One to three 180 mg tablets, once or twice daily, will usually be sufficient to control symptoms; however, the needs of certain individuals may vary markedly from this average. The interval between doses should be at least 6 hours. For optimum control, it may be necessary to use the more rapidly acting regular tablets or syrup in conjunction with extended-release therapy.

*Note:* For information on a diagnostic test for myasthenia gravis, and for the evaluation and stabilization of therapy, please see product literature on edrophonium chloride.

## HOW SUPPLIED

Pyridostigmine Bromide Extended-release Tablets, **180 mg** are available as light brown to pale yellow, capsule-shaped tablets, debossed with W1 on one side and single-scored on the other side.

NDC 68071-5032-3 BOTTLES OF 30

*Note:* Because of the hygroscopic nature of the extended-release tablets, mottling may occur. This does not affect their efficacy.

Store at 20° to 25°C (68° to 77°C) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container. Keep pyridostigmine bromide extended-release tablets in a dry place with the silica gel enclosed.

#### REFERENCES

- 1. Osserman KE, Genkins G. Studies in myasthenia gravis: Reduction in mortality rate after crisis. *JAMA.* Jan 1963; 183:97-101.
- 2. Osserman KE, Genkins G. Studies in myasthenia gravis. *NY State J Med.* June 1961; 61:2076-2085.
- 3. Grob D. Myasthenia gravis. A review of pathogenesis and treatment. *Arch Intern Med.* Oct 1961; 108:615-638.
- 4. Schwab RS. Management of myasthenia gravis. *New Eng J Med.* Mar 1963; 268:596-597.
- 5. Schwab RS. Management of myasthenia gravis. *New Eng J Med.* Mar 1963; 268:717-719.
- 6. Cronnelly R, Stanski DR, Miller RD, Sheiner LB. Pyridostigmine kinetics with and without renal function. *Clin Pharmacol Ther.* 1980; 28: No. 1, 78-81.
- Miller RD. Pharmacodynamics and pharmacokinetics of anticholinesterase. In: Ruegheimer E, Zindler M, ed. *Anaesthesiology*. (Hamburg, Germany: Congress; Sep 14-21, 1980; 222-223.) (Int Congr. No. 538), Amsterdam, Netherlands: Excerpta Medica; 1981.
- 8. Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. *Clin Pharmacol Ther.* 1985;5:495-501.

Distributed by:

Amneal Pharmaceuticals LLC Bridgewater, NJ 08807

Rev. 01-2019-00

## PRINCIPAL DISPLAY PANEL

	• NuCare Pharmaceuticals,		
Packaged B VuCare PI Orange, C Patienalns Fake	NDC: 68071-5032-3 Pyridostigmine Bromide 180mg	Pyridostigmine Bromide 180mg Lot: 000000 NDC: 68071-5032-0 MFR NDC: 0115-1404-08 Exp.: 00000 Serial# 0000000002	
d By: e Pharmaceuti e, CA 92867 <u>Instructions</u> times a	#30 E-R Tablets	Pyridostigmine Bromide 180mg Lot: 000000 NDC: 68071-5032-03 MFR NDC: 0115-1404-08 Exp.: 000000 Serial# 0000000002	
iceuticals, Inc. 167 <u></u>	See manufacturer's label for full list of ingredients	GTIN 00368071503234 Serial# 0000000002 Exp. Date 000000 LOT#: 000000	
hours	Product #: R1830030 Rx Only	Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.	

## PYRIDOSTIGMINE BROMIDE

pyridostigmine bromide tablet, extended release

Product Type       HUMAN PRESCRIPTION DRUG       Item Code (Source)       NDC:68071-5032(NDC:0115- 1404)         Route of Administration       ORAL         Ingredient/Active Moiety         Active Ingredient/Active Moiety         PrRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE - UNIII: 190M69HH21)       Pasis of Strength BROMIDE       Strength         Inactive Ingredient Name       PYRIDOSTIGMINE BROMIDE       Iso mg         CARNAUBA WAX (UNII: R12CBM0EIZ) COPOVIDONE K25-31 (UNII: R12CBM0EIZ)       Ingredient Name       Strength         CARNAUBA WAX (UNII: R12CBM0EIZ)         COPOVIDONE K25-31 (UNII: R12CBM0EIZ)         Stare of Xamau Karawa	Product Inf							
Active Ingredient/Active Moiety Ingredient Name Basis of Strength Streng PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE - PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE - BROMIDE 180 mg Inactive Ingredients Ingredient Name Strength CARNAUBA WAX (UNII: R12CBM0EIZ) COPOVIDONE K25-31 (UNII: S12GBM0EIZ) COPOVIDONE K25-31 (UNII: S12GBM0EIZ) SILICON DIOXIDE (UNII: S17ZGXBU4) Product Characteristics Color yellow (light brown to pale yellow) Silicon DIOXIDE (UNII: ETJ7ZGXBU4) Product Characteristics Flavor Contains Product Characteristics Packaging # tem Code Package Description Marketing Start Date Packaging # tem Code Package Description 06/14/2019 Flavor Marketing Information Marketing Start Marketing End Date	Product Type	•			e		071-5032(N	DC:0115-
Ingredient Name       Basis of Strength       Strengt         PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE -       PYRIDOSTIGMINE BROMIDE       180 mg         Inactive Ingredients       BROMIDE       BROMIDE       180 mg         Inactive Ingredients       Strength       Strength         COPOVIDONE K25-31 (UNII: B12CB00BB)       Strength       Strength         ANHYDROUS LACTOSE (UNII: SYSLH9PMK)       Strength       Strength         MAGNESIUM STEARATE (UNII: T0097M6I30)       SILICON DIOXIDE (UNII: SYSLH9PMK)       Strength         MAGNESIUM STEARATE (UNII: T0097M6I30)       SILICON DIOXIDE (UNII: SYSLH9PMK)       Strength         Shape       OVAL (capsule-shaped)       Size       19mm         Product Characteristics       Imprint Code       W1         Contains       Size       19mm         Plavor       Imprint Code       W1         Contains       30 in 1 BOTTLE: Type 0: Not a Combination       08/14/2019         Marketing End Date       Date       Date         Marketing Category       Application Number or Monograph       Marketing Start       Marketing End Date	Route of Adm	ninistration	ORAL					
Ingredient Name       Basis of Strength       Strengt         PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE -       PYRIDOSTIGMINE BROMIDE       180 mg         Inactive Ingredients       BROMIDE       BROMIDE       180 mg         Inactive Ingredients       Strength       Strength         COPOVIDONE K25-31 (UNII: B12CB00BB)       Strength       Strength         ANHYDROUS LACTOSE (UNII: SYSLH9PMK)       Strength       Strength         MAGNESIUM STEARATE (UNII: T0097M6I30)       SILICON DIOXIDE (UNII: SYSLH9PMK)       Strength         MAGNESIUM STEARATE (UNII: T0097M6I30)       SILICON DIOXIDE (UNII: SYSLH9PMK)       Strength         Shape       OVAL (capsule-shaped)       Size       19mm         Product Characteristics       Imprint Code       W1         Contains       Size       19mm         Plavor       Imprint Code       W1         Contains       30 in 1 BOTTLE: Type 0: Not a Combination       08/14/2019         Marketing End Date       Date       Date         Marketing Category       Application Number or Monograph       Marketing Start       Marketing End Date								
PYRIDOSTIGMINE BROMIDE (UNII: KVI301NA53) (PYRIDOSTIGMINE -       PYRIDOSTIGMINE BROMIDE       180 mg         Inactive Ingredients       Strength         CARNAUBA WAX (UNII: R12CBM0EIZ)       Strength         COPOVIDORE K25-31 (UNII: 59C310MD8B)         ANHYDROUS LACTOSE (UNII: 35Y5LH9PMK)         MAGNESIUM STEARATE (UNII: 59C330MD8B)         SILCON DIOXIDE (UNII: 35Y5LH9PMK)         MACOUNT Colspan="2">Strength         SillCON DIOXIDE (UNII: 51772 6XBU4)         Score       2 pieces         Shape       OVAL (capsule-shaped)       Score       2 pieces         Shape OVAL (capsule-shaped)       Size       19mm         Flavor       Imprint Code       W1         Contains         Packaging         # Item Code       Package Description       Marketing Start       Marketing End Date         Date         Packaging         # Item Code       Package Description       08/14/2019       VI         SillCon Number or Monograph       Marketing Start       Marketing End Date	Active Ingre	edient/Active	Moiety					
JNII:19QM69HH21) BROMIDE BROMIDE BROMIDE BROMIDE CONTINUE 120 FINITION CONTINUE 120 FIN		Ingr	edient Name			Basis of	Strength	Strengt
Ingredient Name       Strength         CARNAUBA WAX (UNII: R12CBM0EIZ)       Strength         COPOVIDONE K25-31 (UNII: D9C330MD8B)       Strength         ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)       Strength         MAGNESIUM STEARATE (UNII: 70097M6I30)       Strength         SILICON DIOXIDE (UNII: ETIJ7Z 6XBU4)       Strength         Strength         OVAL (capsule-shaped)         Size         OVAL (capsule-shaped)         Size         Product Characteristics         Color       yellow (light brown to pale yellow)       Size       19mm         Flavor       19mm         Imprint Code       19mm         NDC:68071-       30 in 1 BOTTLE; Type 0: Not a Combination       08/14/2019       W1         Marketing Information         Marketing Information         Marketing Start Date       Marketing End Date			II: KVI301NA53) (PYRIDOSTIG	MINE -			MINE	180 mg
CARNAUBA WAX (UNII: R12CBM0EIZ)       Image: Composition of the state of the stat	Inactive Ing	jredients						
COPOVIDONE K25-31 (UNII: D9C330MD8B)       Image: Composition of the state of the			Ingredient Name				Stre	ngth
ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)       Image: state of the state			· ·					
MagNesium STEARATE (UNII: 70097M6130)       Image: Constant of the second								
SILICON DIOXIDE (UNII: ETJ7Z 6XBU4)  Product Characteristics Color yellow (light brown to pale yellow) Score 2 pieces Shape OVAL (capsule-shaped) Size 19mm Flavor Contains  VI Contains			•					
Product Characteristics         Color       yellow (light brown to pale yellow)       Score       2 pieces         Shape       OVAL (capsule-shaped)       Size       19mm         Flavor       Imprint Code       W1         Contains       Marketing Start       Marketing End Date         Marketing Information       Marketing Start Category       Marketing End Date	MACHECHIM CT	<b>FEARATE</b> (UNII: 70	097M6I30)					
Color       yellow (light brown to pale yellow)       Score       2 pieces         Shape       OVAL (capsule-shaped)       Size       19mm         Flavor       Imprint Code       VI         Contains       Val       Marketing Start Date       Marketing End Date         NDC:68071-       30 in 1 BOTTLE; Type 0: Not a Combination Product       08/14/2019       Marketing Start Date         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing Start Date								
Shape       OVAL (capsule-shaped)       Size       19mm         Flavor       Imprint Code       W1         Contains       Imprint Code       W1         Kaging       Package Description       Marketing Start Date       Marketing End Date         NDC:68071- 5032-3       30 in 1 BOTTLE; Type 0: Not a Combination Product       08/14/2019       V       V         Marketing Category       Application Number or Monograph Citation       Marketing Start Date       Marketing Start Date       Marketing End Date								
Flavor       Imprint Code       W1         Contains       Imprint Code       W1         Package       Imprint Code       W1         Item Code       Package Description       Marketing Start Date       Marketing End Date         I       NDC:68071- 5032-3       30 in 1 BOTTLE; Type 0: Not a Combination Product       08/14/2019       Imprint Code       Marketing End Date	SILICON DIOXII Product Cha	DE (UNII: ETJ7Z6XE	3U4)					·
Interview of the second secon	SILICON DIOXII <b>Product Ch</b> a Color	DE (UNII: ETJ7Z6XE Aracteristics yellow (light br	3U4) own to pale yellow)			3		
Harketing Code       Package Description       Marketing Start Date       Marketing End Date         NDC:68071- 5032-3       30 in 1 BOTTLE; Type 0: Not a Combination Product       08/14/2019       08/14/2019	SILICON DIOXII <b>Product Ch</b> a Color Shape	DE (UNII: ETJ7Z6XE Aracteristics yellow (light br	3U4) own to pale yellow)		Size	-	19	mm
#       Item Code       Package Description       Marketing Start Date       Marketing End Date         1       NDC:68071- 5032-3       30 in 1 BOTTLE; Type 0: Not a Combination Product       08/14/2019       08/14/2019         Marketing Category         Marketing Category	SILICON DIOXII <b>Product Ch</b> a Color Shape Flavor	DE (UNII: ETJ7Z6XE Aracteristics yellow (light br	3U4) own to pale yellow)		Size	-	19	mm
#       Item Code       Package Description       Marketing Start Date       Marketing End Date         1       NDC:68071- 5032-3       30 in 1 BOTTLE; Type 0: Not a Combination Product       08/14/2019       08/14/2019         Marketing Category         Marketing Category	SILICON DIOXII <b>Product Ch</b> a Color Shape Flavor	DE (UNII: ETJ7Z6XE Aracteristics yellow (light br	3U4) own to pale yellow)		Size	-	19	mm
So32-3       Product       00/14/2013         Marketing Information       Marketing Category       Application Number or Monograph Citation	SILICON DIOXII Product Cha Color Shape Flavor Contains	DE (UNII: ETJ7Z6XE Aracteristics yellow (light br	3U4) own to pale yellow)		Size	-	19	mm
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date	SILICON DIOXII Product Cha Color Shape Flavor Contains Packaging	DE (UNII: ETJ7Z6XE aracteristics yellow (light br OVAL (capsule	3U4) own to pale yellow) -shaped)	Ma	Size Impri	nt Code g Start	19 Wi Market	ing End
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date	SILICON DIOXII Product Cha Color Shape Flavor Contains Packaging # Item Cod	e Pa 30 in 1 BOTTI	BU4) own to pale yellow) -shaped) ckage Description		Size Impri Impri Impri Dat	nt Code g Start	19 Wi Market	ing End
Category Citation Date Date	SILICON DIOXII Product Cha Color Shape Flavor Contains Packaging # Item Cod	e Pa 30 in 1 BOTTI	BU4) own to pale yellow) -shaped) ckage Description		Size Impri Impri Impri Dat	nt Code g Start	19 Wi Market	ing End
ANDA ANDA203184 09/18/2015	SILICON DIOXII	e Pa 30 in 1 BOTTI Product	BU4) own to pale yellow) -shaped) <b>ckage Description</b> .E; Type 0: Not a Combinatio		Size Impri Impri Impri Dat	nt Code g Start	19 Wi Market	ing End
	SILICON DIOXII Product Cha Color Shape Flavor Contains Packaging # Item Cod 1 NDC:68071- 5032-3 Marketing	e Pa 30 in 1 BOTTI Product g Informat Applica	BU4) own to pale yellow) -shaped) ckage Description LE; Type 0: Not a Combination :ion tion Number or Monog	on 08/14	Size Impri orketing Dat /2019 Marketi	nt Code g Start e	19 Wi Market Da	ing End ate

Labeler - NuCare Pharmaceuticals,Inc. (010632300)

Establishment							
Name	Address	ID/FEI	<b>Business Operations</b>				
NuCare Pharmaceuticals, Inc.		010632300	relabel(68071-5032)				

Revised: 2/2021